Geron Corp (NASDAQ:GERN)

CAPS Rating: 3 out of 5

A biopharmaceutical company which is developing first-in-class therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, diabetes and HIV/AIDS.

Recs

0
Player Avatar TruffelPig (< 20) Submitted: 9/10/2012 1:27:07 PM : Underperform Start Price: $1.52 GERN Score: +7.64

With today's failure in the main drug of GERN in cancer treatment I think there is little hope left. I short this until GERN goes bancrupt I think which shouldn't take too long.

Featured Broker Partners


Advertisement